Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 12/2021

01-12-2021 | SARS-CoV-2 | Concise Research Report

Diagnostic Performance of Self-Reported Smell and Taste Disorders Varies with COVID-19 Prevalence in Primary Care Settings

Authors: Paul Sebo, MD MSc, Dagmar M. Haller, MD-PhD, Hubert Maisonneuve, MD

Published in: Journal of General Internal Medicine | Issue 12/2021

Login to get access

Excerpt

Studies in primary care, including our own, showed that patients with COVID-19 frequently complained of smell and/or taste disorders.1, 2 This finding is possibly related to the tropism of SARS-CoV-2 for the nerves of the ENT system.3 In an epidemic context, the high specificity of these two symptoms, taken alone or in combination, could help primary care physicians (PCPs) in their diagnostic approach when examining patients suspected of having COVID-19.4 To our knowledge, the diagnostic contribution of these symptoms in low COVID-19 prevalence periods or settings (< 5%) is unknown. …
Literature
1.
Tudrej B, Sebo P, Lourdaux J, et al. Self-Reported Loss of Smell and Taste in SARS-CoV-2 Patients: Primary Care Data to Guide Future Early Detection Strategies. J Gen Intern Med 2020; 35: 2502–4.CrossRef
2.
Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Oto-Rhino-Laryngol 2020; 277: 2251–61.
3.
Glezer I, Bruni-Cardoso A, Schechtman D, Malnic B. Viral infection and smell loss: The case of COVID-19. J Neurochem 2021; 157: 930–43.CrossRef
4.
Zayet S, Klopfenstein T, Mercier J, et al. Contribution of anosmia and dysgeusia for diagnostic of COVID-19 in outpatients. Infection 2020; 49: 361–5.
Metadata
Title
Diagnostic Performance of Self-Reported Smell and Taste Disorders Varies with COVID-19 Prevalence in Primary Care Settings
Authors
Paul Sebo, MD MSc
Dagmar M. Haller, MD-PhD
Hubert Maisonneuve, MD
Publication date
01-12-2021
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 12/2021
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-021-07141-5

Other articles of this Issue 12/2021

Journal of General Internal Medicine 12/2021 Go to the issue

Original Research

Cigarette Smoking and Risk Perceptions During the COVID-19 Pandemic Reported by Recently Hospitalized Participants in a Smoking Cessation Trial

Perspective

Economic Considerations for Hospital at Home Programs: Beyond the Pandemic

Original Research

The Utilization and Costs of Grade D USPSTF Services in Medicare, 2007–2016

Concise Research Report

‘What happens if I do nothing?’ A Systematic Review of the Inclusion and Quantitative Description of a ‘No Active Intervention’ Option in Patient Decision Aids

Original Research

Prior Immunosuppressive Therapy and Severe Illness Among Patients Diagnosed with SARS-CoV-2: a Community-Based Study

Concise Research Report

Trends and Disparities in Functional Impairment among US Adults Age 55–64, 2002 to 2016
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits